Who Paid My Doc
Andrea Suarez
Family Medicine Madison, WI Medical Doctor
NPI 1942707823 CMS profile 9332648
408 Eagle Hts, Madison, WI 53705
General payments
$17,325
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Andrea Suarez of Madison, WI is reported in the CMS Open Payments database as having received $17,325 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $17,325 | 5 |
Beside peers
- Andrea Suarez
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Andrea Suarez were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Andrea Suarez | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $150 | $41–$543 | $163 |
| 2020 | $0 | $120 | $32–$415 | $114 |
| 2021 | $17,325 | $137 | $35–$551 | $132 |
| 2022 | $0 | $137 | $37–$512 | $149 |
| 2023 | $0 | $149 | $42–$545 | $160 |
| 2024 | $0 | $156 | $44–$560 | $164 |
| 2025 | $0 | $155 | $45–$549 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
1,576
Drug cost
$58,192
Branded share of claims
12.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xifaxan Rifaximin | Brand | 11 | $36,360 | |
| Atorvastatin Calcium | Generic | 177 | $2,350 | |
| Amlodipine Besylate | Generic | 130 | $1,480 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 59 | $1,110 | |
| Gabapentin | Generic | 52 | $1,067 | |
| Levothyroxine Sodium | Generic | 59 | $1,039 | |
| Lisinopril | Generic | 78 | $932 | |
| Fluticasone Propionate | Generic | 47 | $905 | |
| Losartan Potassium | Generic | 59 | $779 | |
| Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide | Brand | 54 | $666 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Wisconsin
Related records
Family Medicine in Wisconsin
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Wisconsin
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.